CCMDS AML in Partnership with CLSG/GCEL
On behalf of the organizing committee, we welcome you to the Canadian Conference on Myelodysplastic Syndromes (CCMDS) and Acute Myeloid Leukemia (AML). We are happy to announce, for the first year, the CCMDS/AML Conference has collaborated with the Canadian Leukemia Study Group (CLSG). CCMDS/AML will take place on September 20-22, 2024 at the Fairmont Palliser Hotel, Calgary, Alberta. This meeting follows on the momentum and success generated by the last several CCMDS/AML meetings.
CCMDS/AML will host international experts in MDS and AML from Europe, the United States and Canada. These leaders will review the newest developments in this rapidly evolving field.
Case presentations will highlight current treatment standards and feature discussions of where the new therapies could be positioned. There will be opportunity for audience participation via polling with members of the clinical faculty featured during the panel discussion. We aim to bring a Canadian perspective to the management of MDS & AML patients. These meetings have clear implications for the delivery of care to patients with MDS and AML in Canada and fosters opportunities for collaboration and research.
The planning committee is looking forward to your input as to ways in which we can work together to optimize the care of our patients.
We look forward to seeing you in Calgary for CCMDS/AML!
Yours truly,
Dr. Michelle Geddes, CCMDS/AML 2024 Chair, Calgary, AB
On behalf of the CCMDS/AML Planning Committee,
Dr. Rena Buckstein, Toronto, ON
Dr. Brett Houston, Winnipeg, MB
Dr. Aly Karsan, Vancouver, BC
Dr. Wendy Lam, Burnaby, BC
Dr. Brian Leber, Hamilton, ON
Dr. Heather Leitch, Vancouver, BC
Ms. Cindy Murray, Toronto, ON
Dr. Lynn Savoie, Calgary, AB
Dr. Andre Schuh, Toronto, ON
Dr. April Shamy, Montreal, QC
Target Audience
This meeting has been designed to meet the educational needs of hematologists, internists, researchers, general practitioners in oncology, practitioners in laboratory medicine, residents, fellows, nurses, pharmacists and other health care providers involved in the management of patients with MDS & AML.
Accreditation:
This event is an Accredited Group Learning Activity (Section 1) as defined by the Maintenance of Certification program of the Royal College of Physicians and Surgeons of Canada.
This activity was approved by the Canadian Association of Medical Oncologists for a maximum of 17 hours.
CCMDS AML Carolyne Delage Young Investigators Award Program
Call for Abstracts
The CCMDS/AML 2024 is a Canadian meeting of hematologists with an interest in treating myeloid malignancies. CCMDS/AML will be held Sept 20-22/24 in Calgary, Alberta. We are inviting submissions for abstracts for the Carolyne Delage Young Investigators Research Award Program.
The CCMDS AML Carolyne Delage Young Investigators Research Awards Program aims to provide educational and research support to residents, fellows and graduate students interested in the area of myelodysplastic syndromes and acute myeloid leukemia. Trainees at any level, fellows and graduate students confirmed by letter of training from their program director, are eligible to submit an abstract of original research projects, informative case reports or series and other projects that address the pathophysiology, prognosis and care of patients with MDS and AML. Abstracts presented at previous meetings, but not in full publication, are allowed for submission. All selected abstracts will be displayed in the Abstract poster board area at conference.
One selected abstract will be presented during a special Carolyne Delage Young Investigators Session on the afternoon of Friday September 20, 2024, at the CCMDS AML conference in Calgary.
Deadline for submission is Monday August 12th, 2024.
Learning Objectives
CCMDS/AML, a collaboration between Canadian Consortium on Myelodysplastic Syndromes and Canadian Leukemia Study Group
At the completion of the meeting, attendees should be able to (MDS):
- Review current understanding of the role of molecular mutations in MDS biology and prognosis
- Review the role of inflammation in MDS pathogenesis and progression
- Review MDS overlap syndromes
- Update treatment strategies in MDS including novel agents
- Gain insight into mechanisms of treatment resistance
- Review the role of intensive therapies and stem cell transplantation in MDS
- Review pre-MDS conditions including CHIP, CCUS, and ICUS
- Review mechanisms of atherosclerosis in the context of cardiac morbidity in MDS
- Review current understanding of the role of iron overload in MDS
- Discuss a Canadian perspective on MDS landscape & treatment
At the completion of the meeting, attendees should be able to (AML):
- Review the biology of AML
- Review novel treatments for AML
- Review the role of leukemic stem cells in AML pathogenesis and progression
- Review cellular therapy for AML
- Review the role of intensive therapies and stem cell transplantation in elderly/t/s-AML, including conditioning regimens and patient selection for these therapies.
- Discuss a Canadian perspective on AML landscape and treatment
Accommodations
Fairmont Palliser Hotel Calgary – SOLD OUT
133 9th Avenue South West, Calgary, AB T2P 2M3
CCMDS/AML is pleased to have negotiated a discounted room rate starting at $289/night + taxes for our delegates.
Please book your room before 19, 2024!
ROOMS ARE SOLD OUT
(Please contact Nancy at nancy@haymatick.com for additional rooms)
To manage an existing reservation, please use the button below or please call +1 403 262 1234 or visit www.fairmont.com/palliser-calgary/ for more information.
